Avalo Therapeutics, Inc. (AVTX) Shareholders’ equity 2016–2025
Avalo Therapeutics, Inc. (AVTX) shareholders’ equity at each fiscal year-end, per SEC filings.
$83.0MFY2025 · since FY2016: $207,002 → $83.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $83.0M | -37.6% |
| FY2024 | $133.0M | +1721.4% |
| FY2023 | $7.3M | +166.9% |
| FY2022 | -$10.9M | -147.3% |
| FY2021 | $23.1M | -6.0% |
| FY2020 | $24.6M | +17.0% |
| FY2019 | $21.0M | +0.4% |
| FY2018 | $20.9M | -25.0% |
| FY2017 | $27.9M | +13358.6% |
| FY2016 | $207,002 | — |
Source: SEC XBRL filings · For reference only · Not investment advice